Literature DB >> 23238972

Nuclear condensation and cell cycle arrest induced by telomerase siRNA in neuroblastoma cells.

Ming-Dar Tsai1, Pei-Rong Chen, Lu-Tai Tien, Yu-Jyun Cai, Yih-Jing Lee.   

Abstract

Neuroblastoma is a type of malignant extracranial tumor that occurs in children. Advanced neuroblastoma, and tumors with MYCN amplification in particular, have poor prognoses. Therefore, it is important to find an effective cure for this disease. Small interfering RNA (siRNA) disrupts gene function by specifically binding to target mRNA. In this study, we used siRNA against telomerase to treat neuroblastoma, to evaluate any anti-proliferative effect on these cells. We evaluated cell viability by WST-1 assay on neuroblastoma cells treated with or without telomerase siRNA. Nuclear condensation, an indicator for apoptotic cells, was determined by DAPI labeling following siRNA treatment. The effectiveness of telomerase siRNA on altering the neuroblastoma cell cycle was detected by flow cytometry. Our results indicated that telomerase siRNA reduces the viability of neuroblastoma cells and increases the percentage of cells in the cell cycle's sub-G1 phase. We found that telomerase siRNA increases the percentage of condensed DNA in neuroblastoma cells. In conclusion, using siRNA against telomerase could be further developed as a therapy for the treatment of neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23238972     DOI: 10.1007/s11060-012-1025-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

Review 1.  Telomeres and telomerase.

Authors:  Simon R W L Chan; Elizabeth H Blackburn
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2004-01-29       Impact factor: 6.237

Review 2.  Signaling pathways that regulate life and cell death: evolution of apoptosis in the context of self-defense.

Authors:  Cristina Muñoz-Pinedo
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 3.  The logic and regulation of cell cycle exit and reentry.

Authors:  D Pajalunga; A Mazzola; A Franchitto; E Puggioni; M Crescenzi
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

4.  Comparison of chromosome telomere integrity in multiple tissues from subjects at different ages.

Authors:  M G Butler; J Tilburt; A DeVries; B Muralidhar; G Aue; L Hedges; J Atkinson; H Schwartz
Journal:  Cancer Genet Cytogenet       Date:  1998-09

Review 5.  Systems biology of apoptosis and survival: implications for drug development.

Authors:  Salvatore Pezzino; Sabrina Paratore; Sebastiano Cavallaro
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

6.  Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months.

Authors:  K Kawa; N Ohnuma; M Kaneko; K Yamamoto; T Etoh; H Mugishima; M Ohhira; J Yokoyama; F Bessho; T Honna; J Yoshizawa; K Nakada; M Iwafuchi; T Nozaki; J Mimaya; T Sawada; T Nakamura; H Miyata; K Yamato; Y Tsuchida
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

7.  Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter.

Authors:  S F Hoare; L A Bryce; G B Wisman; S Burns; J J Going; A G van der Zee; W N Keith
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

8.  A common variant in the telomerase RNA component is associated with short telomere length.

Authors:  Omer T Njajou; Elizabeth H Blackburn; Ludmila Pawlikowska; Massimo Mangino; Coleen M Damcott; Pui-Yan Kwok; Timothy D Spector; Anne B Newman; Tamara B Harris; Steven R Cummings; Richard M Cawthon; Alan R Shuldiner; Ana M Valdes; Wen-Chi Hsueh
Journal:  PLoS One       Date:  2010-09-27       Impact factor: 3.240

9.  Telomerase activity in small-cell and non-small-cell lung cancers.

Authors:  K Hiyama; E Hiyama; S Ishioka; M Yamakido; K Inai; A F Gazdar; M A Piatyszek; J W Shay
Journal:  J Natl Cancer Inst       Date:  1995-06-21       Impact factor: 13.506

10.  Telomerase-independent paths to immortality in predictable cancer subtypes.

Authors:  Stephen T Durant
Journal:  J Cancer       Date:  2012-01-31       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.